John Prendergast

Dr John Prendergast has international experience in commercialising pharmaceuticals for global markets, particularly in the USA. He is chair and co-founder of Palatin Technologies (NYSE: PTN), a US biotechnology company; lead director of Heat Biologics (NASDAQ: HTBX); and co-founder/executive chair of Nejo. Dr Prendergast also held previous US biotechnology board positions particularly as lead director of MediciNova (Nasdaq:MNOV) and Osaka Securities Exchange (#4875) and co-founder/lead director of Avigen. Prior to a career in commercialising pharmaceutical technologies, Dr Prendergast was managing director of Paramount Capital Investments and The Castle Group. Dr Prendergast was also a member of the advisory board of the Institute for the Biotechnology of Infectious Diseases (IBID) at the University of Technology Sydney, now called the ithree Institute.
Bio last updated 30 Apr 2018

Access to our data for John Prendergast is only available to paid subscribers with access.

The search engine is Western Australia's most accurate and comprehensive business listings and searchable database.

John Prendergast is linked to 1 organisation which is included in 1 list - Public Companies - Industrial.

To see the data you will need to .

Total Shareholder Return as at 31/12/18

1 year TSR5 year TSR
555thStrategic Elements-45%-5%
799thWangle Technologies-79%-32%
716 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Source: Morningstar


Non-Executive Director
Year started and most recent title


153rd↑Wangle Technologies$1.2m
156th↑Strategic Elements$1.1m
237 listed industrial companies ranked by revenue.
Source: Morningstar

BNiQ Disclaimer